Hepatic and Extrahepatic Colorectal Metastases Have Discordant Responses to Systemic Therapy. Pathology Data from Patients Undergoing Simultaneous Resection of Multiple Tumor Sites.
chemotherapy
colorectal hepatic and extrahepatic metastases
lung metastases
lymph node metastases
peritoneal metastases
response to chemotherapy
systemic therapy
targeted therapies
tumor regression grade
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
26 Jan 2021
26 Jan 2021
Historique:
received:
31
12
2020
revised:
19
01
2021
accepted:
21
01
2021
entrez:
3
2
2021
pubmed:
4
2
2021
medline:
4
2
2021
Statut:
epublish
Résumé
Systemic therapy is the standard treatment for patients with hepatic and extrahepatic colorectal metastases. It is assumed to have the same effectiveness on all disease foci, independent of the involved organ. The present study aims to compare the response rates of hepatic and extrahepatic metastases to systemic therapy. All consecutive patients undergoing simultaneous resection of hepatic and extrahepatic metastases from colorectal cancer after oxaliplatin- and/or irinotecan-based preoperative chemotherapy were analyzed. All specimens were reviewed. Pathological response to chemotherapy was classified according to tumor regression grade (TRG). We analyzed 45 patients undergoing resection of 134 hepatic and 72 extrahepatic metastases. Lung and lymph node metastases had lower response rates to chemotherapy than liver metastases (TRG 4-5 95% and 100% vs. 67%, Response to chemotherapy of distant metastases from colorectal cancer varies in different organs. Systemic treatment is highly effective for peritoneal metastases, more so than liver metastases, while it has a very poor impact on lung and lymph node metastases.
Sections du résumé
BACKGROUND
BACKGROUND
Systemic therapy is the standard treatment for patients with hepatic and extrahepatic colorectal metastases. It is assumed to have the same effectiveness on all disease foci, independent of the involved organ. The present study aims to compare the response rates of hepatic and extrahepatic metastases to systemic therapy.
METHODS
METHODS
All consecutive patients undergoing simultaneous resection of hepatic and extrahepatic metastases from colorectal cancer after oxaliplatin- and/or irinotecan-based preoperative chemotherapy were analyzed. All specimens were reviewed. Pathological response to chemotherapy was classified according to tumor regression grade (TRG).
RESULTS
RESULTS
We analyzed 45 patients undergoing resection of 134 hepatic and 72 extrahepatic metastases. Lung and lymph node metastases had lower response rates to chemotherapy than liver metastases (TRG 4-5 95% and 100% vs. 67%,
CONCLUSIONS
CONCLUSIONS
Response to chemotherapy of distant metastases from colorectal cancer varies in different organs. Systemic treatment is highly effective for peritoneal metastases, more so than liver metastases, while it has a very poor impact on lung and lymph node metastases.
Identifiants
pubmed: 33530435
pii: cancers13030464
doi: 10.3390/cancers13030464
pmc: PMC7865224
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Ann Surg Oncol. 2016 Apr;23(4):1352-60
pubmed: 26714946
Cancer Biol Ther. 2018 Aug 3;19(8):659-663
pubmed: 29580164
Surgery. 2018 Jun;163(6):1238-1244
pubmed: 29455841
Ann Surg Oncol. 2012 Sep;19(9):2786-96
pubmed: 22622469
BMC Cancer. 2019 Feb 26;19(1):173
pubmed: 30808323
Ann Surg Oncol. 2015 May;22(5):1585-92
pubmed: 25373535
J Clin Oncol. 2009 Apr 10;27(11):1829-35
pubmed: 19273699
Ann Thorac Surg. 2018 Jun;105(6):1605-1612
pubmed: 29518384
Ann Oncol. 2016 Aug;27(8):1386-422
pubmed: 27380959
Ann Surg Oncol. 2020 Aug;27(8):2877-2885
pubmed: 32144619
Cancer Med. 2016 Feb;5(2):256-64
pubmed: 26715198
Lancet Oncol. 2016 Dec;17(12):1709-1719
pubmed: 27743922
J Clin Oncol. 2008 Aug 1;26(22):3672-80
pubmed: 18669451
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
Ann Surg. 2015 May;261(5):956-60
pubmed: 24950280
Ann Surg. 2004 Dec;240(6):1052-61; discussion 1061-4
pubmed: 15570210
Ann Surg Oncol. 2010 Oct;17(10):2714-9
pubmed: 20405223
Lancet Oncol. 2021 Feb;22(2):256-266
pubmed: 33476595
Ann Surg Oncol. 2014 Apr;21(4):1276-86
pubmed: 24346766
Ann Thorac Surg. 2014 Oct;98(4):1238-45
pubmed: 25106681
Lancet. 2008 Mar 22;371(9617):1007-16
pubmed: 18358928
Br J Surg. 2015 May;102(6):691-9
pubmed: 25789941
Hepatobiliary Pancreat Dis Int. 2016 Apr;15(2):216-9
pubmed: 27020639
Oncotarget. 2016 Apr 19;7(16):21591-600
pubmed: 26943031
Ann Oncol. 2015 Apr;26(4):702-708
pubmed: 25538173
Ann Surg. 2013 May;257(5):800-6
pubmed: 23360920
HPB (Oxford). 2017 Sep;19(9):775-784
pubmed: 28625391
Ann Oncol. 2007 Feb;18(2):299-304
pubmed: 17060484
Ann Surg. 2011 Feb;253(2):349-59
pubmed: 21178761
J Cancer Res Clin Oncol. 2020 Mar;146(3):545-553
pubmed: 32036456
Eur J Cancer. 2016 Jan;53:155-62
pubmed: 26751236
Ann Surg. 2017 Jan;265(1):158-165
pubmed: 28009741
Ann Surg Oncol. 2012 Jun;19(6):2035-44
pubmed: 22219066
Ann Surg Oncol. 2017 Mar;24(3):705-720
pubmed: 28058545
Ann Surg. 2013 Nov;258(5):731-40; discussion 741-2
pubmed: 24045448
World J Surg. 2018 Aug;42(8):2651-2659
pubmed: 29423737
Dig Surg. 2019;36(4):340-347
pubmed: 29879717
J Am Coll Surg. 2011 Jul;213(1):62-9; discussion 69-71
pubmed: 21700179
N Engl J Med. 2014 Oct 23;371(17):1609-18
pubmed: 25337750
Ann Surg Oncol. 2018 Jun;25(6):1676-1685
pubmed: 29488188
Oncologist. 2012;17(10):1225-39
pubmed: 22962059
JAMA Oncol. 2017 Jul 13;3(7):e170278
pubmed: 28542671